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ABSTRACT
Hyperthermia has a number of biological effects that sensitize tumors to 
radiotherapy in the range between 40-44 °C. One of these effects is heat-induced 
degradation of BRCA2 that in turn causes reduced RAD51 focus formation, which 
results in an attenuation of DNA repair through homologous recombination. 
Prompted by this molecular insight into how hyperthermia attenuates homologous 
recombination, we now quantitatively explore time and temperature dynamics of 
hyperthermia on BRCA2 levels and RAD51 focus formation in cell culture models, 
and link this to their clonogenic survival capacity after irradiation (0-6 Gy). For 
treatment temperatures above 41 °C, we found a decrease in cell survival, an 
increase in sensitization towards irradiation, a decrease of BRCA2 protein levels, and 
altered RAD51 focus formation. When the temperatures exceeded 43 °C, we found 
that hyperthermia alone killed more cells directly, and that processes other than 
homologous recombination were affected by the heat. This study demonstrates that 
optimal inhibition of HR is achieved by subjecting cells to hyperthermia at 41-43 °C 
for 30 to 60 minutes. Our data provides a guideline for the clinical application of novel 
combination treatments that could exploit hyperthermia’s attenuation of homologous 
recombination, such as the combination of hyperthermia with PARP-inhibitors for 
non-BRCA mutations carriers.
INTRODUCTION
Hyperthermia is an anti-cancer treatment during 
which external heat sources are employed to treat tumors. 
During the treatment, specialized equipment is used to 
regionally heat the tumor to a final temperature in the 
range of 40-44 °C [1], which is a safe and effective way 
to enhance the effectiveness of radiotherapy and some 
types of chemotherapy, such as cisplatin, carboplatin, 
cyclophosphamide, ifosfamide, melphalan and mitomycin 
C [2, 3]. Hyperthermia’s sensitization effects towards 
radiotherapy and chemotherapy can be attributed to a 
plethora of biological effects in the tumor, both on a 
macroscopic and microscopic scale. Research that aims 
to elucidate the biological effects of heat has the potential 
to revolutionize the way in which hyperthermia will be 
employed in a clinical setting [4–8].
One of the effects of hyperthermia described more 
recently is the induction of degradation of the BRCA2-
protein [9]. BRCA2 is essential for repair of DNA double 
strand breaks via homologous recombination (HR) 
[10]. HR faithfully restores these breaks by copying the 
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information from an intact copy of the damaged DNA, 
a process catalyzed by the protein RAD51 [11]. BRCA2 
is necessary for the loading of RAD51 onto DNA breaks 
and by degrading BRCA2, hyperthermia causes aberrant 
localization of RAD51 [9]. This, in turn, causes the 
attenuation of DNA repair via HR, which at least partly 
explains hyperthermia’s sensitizing effects towards 
radiotherapy, the latter being based on the creation of an 
overload of cytotoxic DNA breaks in tumor cells. DNA 
repair pathways can counteract the cytotoxicity, and 
thus, by degrading BRCA2, hyperthermia provides a 
window of opportunity to leave DNA damage unrepaired. 
Moreover, hyperthermia-mediated BRCA2 degradation 
creates specific opportunities to increase treatment 
efficacy, because it induces a localized environment of 
HR-deficiency. This could potentially be exploited by 
new treatment regimens that reduce cancer treatment side-
effects, such as combination of hyperthermia with new 
classes of indirect double-strand break inducing agents, 
like PARP-inhibitors [12, 13].
Before exploiting hyperthermia-mediated atten-
uation of HR in a clinical setting, it is important to 
understand the dynamics of BRCA2 degradation and 
HR-efficiency upon exposures to different temperatures 
and treatment lengths, or, thermal doses. By using a set 
of in vitro experiments, we systematically investigated 
the effects of various thermal doses (ranging from 
40-44 °C for up to four hours) on HR-parameters such 
as BRCA2 degradation and RAD51 focus formation, and 
we examined the extent of cellular sensitization towards 
radiation. Our findings provide insight into threshold 
and saturation levels of BRCA2 degradation upon heat 
treatment and thereby give insight into the relation 
between thermal dose and HR-efficiency.
RESULTS
Thermal dose is a determinant for 
radiosensitisation
To investigate the influence of thermal dose on HR, 
we first established the thermal doses to be used in this 
study (Table 1). Because we are interested in the influence 
of thermal doses currently achieved and aimed for in a 
clinical setting, we selected them based on temperatures 
in the range of 40-44 °C, and on the current duration of 
60 minutes. Additional lengths of treatment were chosen 
to determine an optimum dose for HR-inhibition.
To provide a framework for the assays in which 
we will determine inhibition of HR by hyperthermia, we 
established the ability of these selected thermal doses 
to kill cells directly, and determined their capability to 
sensitize cells to irradiation. To get a general overview of 
the biological principles that guide inhibition of HR by 
hyperthermia, we combined the results of four different 
cell lines. We started by establishing colony survival 
curves of three different cell lines that represent various 
cancer types that are treated with hyperthermia: BLM 
(melanoma), HeLa (cervix) and FaDu (head and neck), 
and a cell line that represents a p53-negative tumor: 
simian virus 40-immortalized fibroblasts (VH10-SV40). 
We treated the cells with the selected thermal doses and 
with doses of radiation ranging from 0 – 6 Gy. Consistent 
with previous studies [14–16], the colony plating 
efficiency for each cell line was reduced after treatment 
with temperatures higher than 40 °C (Figure 1A), 
demonstrating hyperthermia’s ability to kill cells directly.
To closely examine radiosensitisation by hyper-
thermia, we normalized each colony survival curve 
belonging to a certain thermal dose for plating efficiency 
at 0 Gy to 100% (Supplementary Figure 1). We then 
combined the data points from all four cell lines, 
and fitted a linear-quadratic curve to the pooled data 
(Figure 1B) [17]. This analysis resulted in an overview of 
the response to heat and irradiation in the employed cell 
lines: hyperthermia at 40 °C failed to increase sensitivity 
to irradiation, indicated by the prediction of one curve 
to explain the data variation [17]. For all thermal doses 
employing temperatures higher than 41 °C multiple curves 
were obtained, indicating these thermal doses sensitized 
the tumor cells to irradiation. The maximum extent of 
radiosensitisation at 41 °C was reached after two hours 
of treatment, while the same effect was already reached 
after one hour at 42 °C. Doubling the treatment times 
did not increase radiosensitisation any further, indicating 
a saturation of the effects of heat over time. The time-
dependent saturation was not observed when cells were 
treated with 43 °C, 43.5 °C or 44 °C (Figure 1B).
Temperatures higher than 40 °C cause significant 
degradation of functional BRCA2 proteins
Hyperthermia at 42.5 °C inhibits HR by inducing 
proteasomal degradation of the BRCA2 protein [9]. To 
study the effects of thermal dose on HR, we started by 
examining the ability of the selected thermal doses to 
induce degradation of the BRCA2 protein, by measuring 
the BRCA2-protein levels in whole cell extracts from 
the four cell lines treated with the thermal doses by 
immunoblot (Figure 2A). We quantified the BRCA2-
signals on the immunoblot and normalized these to the 
signal at 37 °C (Figure 2B). Although each thermal dose 
had an effect on BRCA2 protein level, the extent of the 
effect was quite different. For the four cell lines tested, 
the lowest mean BRCA2 protein level (22%) was reached 
after 60 minutes treatment at 43 °C, while as much as 
64% of the BRCA2 signal remained after four hours 
of treatment at 40 °C (Figure 2B). This indicates that 
BRCA2 degradation is dependent on the applied thermal 
dose, and presumably, that treatment at 40 °C might be 
insufficient to achieve a significant reduction in BRCA2 
protein levels and thereby in HR. Upon examination of 
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Table 1: Contains an overview of the thermal doses employed in this study
Temperature Time 0 (37 °C) Time 1 Time 2 Time 3
40 °C 0 min 60 min 120 min 240 min
41 °C 0 min 60 min 120 min 240 min
42 °C 0 min 30 min 60 min 120 min
43 °C 0 min 15 min 30 min 60 min
43.5 °C 0 min 15 min 30 min 60 min
44 °C 0 min 15 min 30 min 60 min
Figure 1: Plating efficiency and colony cell survival at different thermal doses. Four different cell lines (BLM, HeLa, FaDu 
and VH10-SV40) were submitted to hyperthermia and irradiated afterwards in six independent experiments; one for each temperature. The 
data points and error bars represent mean ± SEM of all pooled cell lines and the connecting curve is the result of a fitted regression. Multiple 
curves were predicted if the regression parameters differed significantly from each other (p<0.05). Exact p-value is embedded in the graphs. 
(A) Plating efficiencies at 0 Gy for all temperatures, normalized to 37 ˚C. Curves were predicted by linear regression and the inset graph 
shows the predicted slope of the regression analysis (Mean ± SD). (B) Surviving fractions upon irradiation, normalized to 0 Gy for each 
thermal dose. The curves are predictions made by linear-quadratic regression. At 40 °C, the single curve explains the variation in the data. 
Between the experiments, one regression line was predicted to explain survival towards irradiation at 37 ˚C. Clonogenic survival curves for 
the individual cell lines can be found in Supplementary Figure 1.
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the BRCA2 protein levels after treatment for 60 minutes at 
the different temperatures, we noticed the most significant 
decrease in the level between 41 °C and 42 °C (Figure 2C). 
Interestingly, when temperatures surpassed 42 °C, the 
degradation of BRCA2 observed in the whole cell lysates 
seemed similar or even less efficient than at 42 °C itself, 
which is especially pronounced in FaDu cells (Figure 2C).
We therefore investigated whether the BRCA2-
signal in the whole cell extract at temperatures exceeding 
43 °C represents a functional pool of the BRCA2 
protein. Since degradation of BRCA2 is mediated by the 
proteasome, a heat-mediated malfunction of proteasomes 
could lead to a failure to detect declining BRCA2-signals 
in a whole cell extract. When the proteasome inhibitor 
Figure 2: The BRCA2 protein is degraded at temperatures higher than 40 ˚C. Cells from four different lines BLM (circle), 
HeLa (square), FaDu (triangle), VH10-SV40 (inverted triangle) were submitted to hyperthermia and subsequently lysed in six separate 
experiments; one for each temperature. (A) BRCA2-signals of all separate samples on cropped immunoblots. PARP-1 is used as a loading 
control. (B) Quantification of BRCA2-protein signals from A Each hyperthermia-treated sample is represented as a percentage of the 
BRCA2 signal at 37 ˚C. The error bars denote mean ± SEM. The statistical differences relative to 37 ˚C were determined by ANOVA 
and followed by Tukey’s Multiple Comparison Test. (C) Quantification of BRCA2 after 60 minutes of a given temperature. Statistical 
differences were determined by ANOVA and followed by Tukey’s Multiple Comparison test.
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MG132 is added to cells previous to hyperthermia 
treatment, the BRCA2-protein levels are rescued in a 
whole cell extract [9]. However, when the cell lysates 
from cells treated with MG132 and hyperthermia are 
fractionated, the entire fraction of protected BRCA2 
is found in the pellet instead of in the supernatant, 
indicating that the heat caused the protein to become 
insoluble (Figure 3A). To investigate what happens with 
the BRCA2-proteins found at 44 °C, we performed the 
same simple fractionation of HeLa cells treated with the 
thermal doses employing temperatures of 42 °C and 44 °C 
(Figure 3B and 3C).
The reduction of the BRCA2 signal in the whole 
cell extract in this experiment was clearly visible when 
the cells were treated with 42 °C and 44 °C (Figure 3B). 
However, cells treated for 60 minutes at 42 °C seemed 
to have lower BRCA2-levels than cells treated for 
60 minutes at 44 °C, confirming our results from Figure 
2C. Strikingly, the localization of BRCA2 in the extracts 
was very different: we found that the BRCA2 levels in the 
supernatant were lower at 44 °C than at 42 °C, indicating 
that the higher temperature is a stronger inducer of 
BRCA2-degradation (Figure 3C and 3D). In contrast to 
the supernatant, the BRCA2 protein detected in the pellet 
Figure 3: BRCA2 moves to an insoluble fraction after treatment with MG132 or 44 ˚C. (A) BRCA2 protein levels at 37 ˚C 
and 42 ˚C in HeLa cells treated with or without 50 μM MG132 on cropped immunoblots. Signals shown are from the whole cell extract 
(left), and from two fractions after centrifugation: the supernatant (middle) and in the pellet fraction (right). HSP90 is used as a loading 
control. (B) BRCA2 protein levels on cropped immunoblots at 42 ˚C (upper panel) and 44 ˚C (lower panel) in HeLa cells in the whole cell 
extract (left), and from the two fractions after centrifugation: the supernatant (middle) and in the pellet fraction (right). HSP90 is shown 
as a loading control. (C) Quantification of BRCA2 signals in B, corrected for the 37 ˚C control. A linear-quadratic regression indicates 
three separate curves for each series of measurements, indicating a significant difference in BRCA2-protein levels in the whole cell extract, 
supernatant and pellet. The error bars denote mean ± SEM obtained in three experiments. (D) Bars zoom in on the 60-minute treatment 
point in C. Statistical differences of column pairs were determined using a student’s t-test.
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increased over time when temperature was set from 37 
to 44 °C, while it decreased over time when cells were 
treated with 42 °C (Figure 3C). This finding indicates that 
although the BRCA2 protein is still present in the whole 
cell extract at the higher temperatures, it represents a pool 
of protein that has aggregated in a fraction that ends up in 
the pellet, and is therefore unlikely to be functional.
Localization of RAD51 in cells is differentially 
affected by thermal dose
Because we found different levels of BRCA2 
protein in response to different thermal doses, and found 
that temperatures exceeding 43 °C did not completely 
eradicate BRCA2 protein levels in the whole cell extract 
(Figure 3), we investigated the presence of RAD51 foci 
upon treatment with the different thermal doses. These 
foci represent the localization of the RAD51-protein 
onto DNA double strand breaks and are a read-out for 
effectivity of HR, in particular for the functionality of the 
BRCA2-protein [18]. Correlating to BRCA2-degradation 
upon hyperthermia treatment (41-42 °C), RAD51 fails 
to localize onto double strand breaks in cells treated at 
these temperatures [9]. To investigate the appearance and 
behavior of RAD51 foci upon treatment with the various 
thermal doses, we treated HeLa cells with these doses, 
irradiated them with 4 Gy, and fixed them either 30, 60 
or 120 minutes after the irradiation. HR requires a copy 
of the damaged DNA, usually the sister chromatid, and 
is therefore limited to the S- and G2-phase of the cell 
cycle [11]. Therefore, to confirm the cells’ ability to form 
RAD51 foci, we used a positive signal for incorporated 
EdU as a prerequisite for cells to be analyzed.
Upon examining the RAD51 signal in the EdU-
positive cells, we found three very distinguished foci-
patterns, which we refer to as Category 1-3 foci. Cells in 
Category 1 presented with many large foci, or “normal”, 
based on our extensive experience [19–21]. Cells with the 
Category 2 focus pattern displayed fewer, but quite large 
foci. The Category 3 focus pattern was represented by 
cells with many, but mostly very small foci (Figure 4A). 
To objectively describe these focus structures, we designed 
an image analysis tool that measures several aspects of 
RAD51 foci in a cell nucleus: the number of foci, their 
average area and their average intensity (Supplementary 
Figure 2). Since both area and intensity can be used to 
classify the response of the foci to temperature, we 
combined them by multiplication, resulting in the mean 
integrated density per focus per nucleus. We plotted 
the integrated density and the number of RAD51 foci 
per cell in a 2D histogram (Figure 4B). While there is 
little to no difference between cells that received heat 
treatment at 40 °C or treatment at 37 °C, cells treated with 
hyperthermia at the higher temperatures (indicated by the 
cloud of red points), shifted away from the cells treated 
at 37 °C (cloud of blue points) (Figure 4B). Compared to 
cells that were treated at 37 °C, cells that were treated with 
41 °C, 42 °C, or, up to 15 minutes with 43 °C or 43.5 °C 
had mostly fewer foci (Category 2) (Figure 4B). However, 
cells treated with 44 °C or with more than 15 minutes at 43 
or 43.5 °C had foci that were smaller in size and intensity 
(Category 3) (Figure 4B).
Upon examination of the Category 3-type foci, 
we noticed that they also were present in cells that 
had not been irradiated (Figure 4C), indicating that 
they form spontaneously upon heat treatment. The 
Category 3 RAD51 foci have been described earlier as 
a representation of stalled replication forks, which are 
able to form independently of functional BRCA2 protein 
[22]. These structures might therefore be additional proof 
for the hypothesis that hyperthermia with temperatures 
exceeding 43 °C causes problems in the S-phase of the 
cells [16]. Concordantly, we found that cells with Category 
3 foci had a less intense EdU-signal compared to cells that 
had normal foci (Category 1) or less foci (Category 2) 
(Supplementary Figure 2E). The EdU-signal did recover 
two hours after stopping hyperthermia treatment, hinting 
that the problems in S-phase could be reversible over time. 
This combined evidence suggests that the disappearance 
of the Category 1 RAD51 foci after treatment with 
temperatures higher than 40 °C indicates inhibited HR, 
and that the Category 3 foci represent another effect of 
hyperthermia.
DISCUSSION
The elucidation of the mechanisms of the biological 
processes responsible for the sensitizing effect of heat 
towards radiotherapy and various chemotherapies is an 
active field of research. Among these processes DNA 
repair pathways are attractive targets of hyperthermia 
because their activity modulates the cytotoxicity of DNA 
breaks in tumor cells, on which the efficacy of radiation 
and chemotherapy is based [23]. Although many DNA 
repair pathways are thought to be affected by heat, one 
pathway is of specific interest in this context: HR. This 
is because the discovery that hyperthermia can be used to 
locally and on demand inhibit the activity of the HR DNA 
repair pathway opens up avenues to novel combination 
therapies; specifically the combination of hyperthermia 
with PARP-inhibitors. PARP-inhibitors selective kill 
HR-deficient cells and are currently clinically applied for 
patient with HR-defective tumors due to genetic BRCA 
deficiency [24–26]. Inhibition of HR by hyperthermia 
carries the promise that PARP-inhibitors can be 
successfully used in much broader patient populations, 
as it will temporarily inactive HR, irrespective of the 
patient’s genetic make-up [9, 12].
In this study, we systematically explored the influence 
of various thermal doses on HR by a set of in vitro 
experiments. We used two parameters of HR-effectivity: 
BRCA2 protein levels and RAD51 focus formation upon 
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irradiation, and established survival curves at the same 
thermal doses to relate HR parameters to a functional 
outcome (Supplementary Table 1). Based on the obtained 
data employing the thermal doses, we can describe three 
distinct responses of HR towards hyperthermia.
The first response is a presumed failure to 
effectively attenuate HR. Cells heated at 40 °C have more 
than 60% of the BRCA2 protein relative to the non-heated 
cells, and the formation of RAD51 foci is barely affected 
by this temperature. This correlates with the finding that 
hyperthermia at 40 °C does not significantly increase 
the sensitivity of the cells to irradiation. With respect to 
the survival results, it should be noted that the average 
treatment temperatures currently reached in the clinic, 
ranging between 40 and 41 °C, does strongly enhance 
treatment outcome [27–32]. This could be explained by 
two reasons, the first being that the cells in culture are 
treated with hyperthermia and radiotherapy only once, 
Figure 4: RAD51 foci behave differently depending on the thermal dose. (A) Representative pictures of RAD51-staining 
pattern upon 4 Gy irradiation in EdU-positive nuclei of HeLa cells. The RAD51 pattern shown in picture 1 is characterized as ‘normal’. 
In picture 2 only few foci can be seen, and in picture 3, many, but mostly very small foci can be distinguished. (B) 2D-representation of 
measured focus-structures in EdU-positive cells. Each dot represents a cell, with on the X-axis the number of foci and on the Y-axis the mean 
integrated density per focus. Thermal doses are indicated with the different colors. A shift of the dot-cloud represents a different appearance 
or, qualification of the RAD51 focus. (C) Representative pictures of RAD51-staining pattern in EdU-positive nuclei in unirradiated cells.
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thus even small, non-significant differences in our colony 
survival assay could result in larger, significant effects 
when treatment is repeated multiple times, as is the case 
in the clinic. The second explanation is that hyperthermia 
has multiple biological effects, including increased blood 
flow [33], increased oxidation [34], and activation of the 
immune system [35], which are obviously not taken into 
account in our in vitro experimental set-up, but might very 
well mediate the treatment outcome in patients treated 
with hyperthermia at lower temperatures [5–8].
The second response group is characterized by 
an attenuation of HR, and presents itself when cells are 
treated with 41 °C, 42 °C or with 15 or 30 minutes at 43 
°C. At 41 °C, 60% of the baseline BRCA2 levels remain 
after 60 minutes of treatment, and continue to drop with 
longer treatment times, as do the number and integrated 
density of RAD51 foci. Moreover, cells are sensitized to 
irradiation when they are treated for 60 minutes at 41 °C, 
and this effect can be exaggerated when cells are treated 
for two hours. However, an additional two hours results 
only in a small decrease in survival, indicating a saturation 
of the hyperthermia-mediated effects on the cells. The 
effects of heat on cell survival and on HR in cells treated 
with hyperthermia at 42 °C, or for 15-30 minutes at 43 °C 
are similar to those in cells treated with 41 °C, but more 
rapid.
The last group within the set of thermal doses 
employed here encompasses the reaction of cells that are 
subjected to 60 minutes at 43 °C, or temperatures higher 
than 43 °C. These thermal doses seem to not only induce 
HR-deficiency, but affect the cells in many more ways 
[36]. For example, consistent with previous studies, we 
find that heat’s ability to directly kill cells and sensitize 
to irradiation is increased, and keeps doing so with longer 
treatment length [14, 15]. In contrast, BRCA2 protein 
levels in the whole cell extract cease to decrease over 
time after the initial drop. However, similar to when cells 
are treated with a proteasome inhibitor, treatment with 
hyperthermia at 44 °C causes BRCA2 to accumulate 
in a pellet fraction, while the amount of BRCA2 in the 
supernatant cell fraction keeps decreasing over time. This 
could be explained by possible defects in the functionality 
of the proteasome, which interferes with the molecular 
removal of unfolding BRCA2 proteins [37]. Consistent 
with this reaction, RAD51 focus morphology, the read-
out used to determine functionality of BRCA2, alters 
greatly in this last group. We show that foci become much 
smaller in size and somewhat less in intensity and that 
they appear independently of irradiation, indicating they 
form spontaneously upon heat. These structures resemble 
RAD51 foci described before to form independent of 
the BRCA2 protein, and could be stalled replication 
forks [22]. The possibility that hyperthermia > 43 °C 
directly affects progression in S-phase has previously 
been described, and is supported by the low intensity 
of the EdU-signal in cells treated in our assays, which 
is indicative of a lack in DNA synthesis [16]. All these 
findings prove that many more biological mechanisms 
than HR are affected by temperatures surpassing 43 °C 
and that these mechanisms result in a lower specificity of 
the heat treatment.
Concluding, our study demonstrates that if 
hyperthermia treatment is aimed at optimally inhibiting 
HR, the temperature which should be strived for is 42 
°C. The minimal thermal dose to achieve defects in this 
DNA repair pathway is 41 °C for one hour, but it is not 
necessary to surpass 30 minutes at 43 °C. Taking into 
consideration that in current hyperthermia treatments 
temperatures higher than 43 °C are rarely reached in the 
patient [31], our findings can be regarded as reassuring 
of the current clinical guidelines and possibilities, but 
can be used to guide technological development of 
next generation hyperthermia systems. Moreover, it 
demonstrates that BRCA2 degradation and RAD51 
focus formation could both be potential biomarkers 
for efficiency of hyperthermia treatment. However, the 
acquired data will be of particular interest as a guideline 
for potential clinical application of anti-cancer strategies 
that exploit the heat-mediated attenuation of HR, such 
as PARP-inhibitors [24, 25] or proton therapy [38, 39], 
will be combined with hyperthermia in a clinical setting 
[8, 12].
MATERIALS AND METHODS
Experimental set-up, hyperthermia and 
irradiation
We studied the effects of hyperthermia on HR 
by exposing cells in 60 mm petri dishes to increased 
temperatures ranging from 40-44 °C in an incubator with 
a controlled atmosphere (5% CO2 and 20% O2) set at the 
appropriate temperature. Indicated treatment times always 
exclude the 15 minutes required for the medium to reach 
the set temperature. The control samples were treated 
at 37 °C. The cells were exposed to γ-irradiation from 
a caesium-137 source with a dose rate of 0.64 Gy/min 
within 15 minutes after hyperthermia treatment.
Cell culture
The following four human cell lines were used: 
BLM, HeLa, FaDu and VH10-SV40. All cell lines 
were cultured in a 1:1 mixture of DMEM (4.5 g/L 
Glucose, with Ultraglutamine 1) and Ham’s F-10 
(BioWhittaker™), supplemented with 10% fetal calf 
serum and 1% penicillin/streptomycin (Sigma-Aldrich), 
and were maintained in an incubator set at 37 °C and 
with an atmosphere of 5% CO2 and 20% O2. Frozen 
aliquots from same passages were used to minimize 
experimental variation. The cells were mycoplasma-free 
and distinguished by morphology.
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Clonogenic assays
Cells were allowed to recover from freezing 
by being cultured for six days: after thawing on day 
one, the cells were split on day 2 and were allowed to 
grow exponentially. Finally on day 5, 24 hours prior 
to seeding the clonogenic assay, 2*106 BLM or Hela 
cells and 3*106 FaDu or VH10-SV40 were seeded in 
10 cm dishes. At the end of the sixth day, cells were 
trypsinized, counted with a coulter counter and seeded 
in triplicates at different concentrations in 60 mm 
dishes; for the control irradiation (0 Gy), 200 BLM 
or HeLa cells were seeded, or 300 for either FaDu or 
VH10-SV40. The amount of seeded cells was doubled 
for each 2 Gy increase in irradiation dose. The cells 
were allowed to attach overnight (~14 h) and were 
treated with the different thermal doses and irradiation 
the next morning. Cell colonies were allowed to form 
for 10 days (HeLa and BLM) or 20 days (FaDu and 
VH10-SV40), after which they were fixed and stained 
in 45% methanol, 45% dH2O, 10% Acetic acid and 
0.25% Coomassie Brilliant Blue (Sigma-Aldrich). 
Colonies containing more than 30 cells were counted 
using a stereomicroscope.
Cell lysis and protein assay
The day before the experiment, 0.8*106 (BLM and 
Hela) or 1.2*106 (FaDu and VH10-SV40) cells were 
seeded in a 60 mm dish. All cell lysates were made 
within 30 minutes after hyperthermia treatment, and 
were in the incubator together with the cells used for 
clonogenic survival or immunofluorescence analysis. 
After washing with PBS, the cells were scraped and 
then lysed in Laemmli sample buffer (2% SDS, 10% 
Glycerol and 60 mM Tris pH 6.8) and heated at 95 °C 
for 5 minutes. The sample was passed through a syringe 
several times to reduce viscosity.
For fractionation experiments, cells in 15 cm 
dishes were treated with MG132 (Calbiochem) one 
hour before the start of hyperthermia, or without 
MG132 at the indicated temperatures. Immediately 
following treatment, the cells were lysed in NETT 
buffer (50 mM Tris-HCl pH7.5, 100 mM NaCl, 5mM 
EDTA 0.5% Triton-X-100, 1x protease inhibitors 
(Complete, Roche®) and 1 mM pefabloc). After 30 
minutes, the cells were scraped and centrifuged at 
12000 rpm for 15 minutes at 4 °C. After centrifugation, 
the pellet and supernatant were separated and the pellet 
was resuspended in PBS. Laemmli buffer was added 
to both samples and the mixture was boiled at 95 °C 
for 5 minutes. Before immunoblotting, the protein 
concentration was estimated using the Lowry protein 
assay [40], after which protein samples were prepared 
by adding loading buffer (final concentration: 0.01% 
bromophenol blue and 0.5% β-mercaptoethanol).
Immunoblotting
The samples were run on an SDS-PAGE gel or a 
3-8% Tris-Act gel (Novex, ThermoFisher Scientific). 
Protein transfer on a PVDF membrane was achieved 
by wet blotting at 300 mA for two hours at 4 °C, 
using transfer buffer (0.4 M Glycine, 5 mM Tris, 20% 
Methanol). After transfer, the membrane was blocked 
in 3% dry skimmed milk in PBS with 0.05% Tween-20. 
The primary antibody was incubated overnight at 4 °C 
and the secondary antibody was incubated for 1-2 hours 
at room temperature. After adding ECL substrate (1:1 
mixture of A: 0.1M Tris-HCl pH 8.5, 2.5 mM Luminol, 
0.4 mM p-Coumaric acid and B: 0.1 M Tris-HCl pH 8.5, 
0.02% hydrogen peroxide), blots were imaged in Alliance 
4.7 (Uvitec Cambridge). The antibody signals from the 
immunoblots were quantified using the ‘Analyze Gels’ 
tool in FIJI (Image J1.50i, [41]). Equal protein loading 
was always checked by staining the post-transfer gel 
with Colloidal Coomassie (0.008% Coomassie Brilliant 
Blue G-250 and 0.35% glacial HCl in distilled water) by 
heating for ~25s, shaking for 30 minutes, and subsequent 
destaining using distilled water.
EdU incorporation and cell fixation
One day prior to the experiment, 0.4*106 Hela 
cells were seeded in a coverslip-containing 30 mm dish. 
The cells were fixed after hyperthermia treatment and 
irradiation. To distinguish S-phase cells, 10 μM EdU 
(Invitrogen) was added to the cells 45 minutes prior to 
fixation. After the indicated time after irradiation, the 
cells were rinsed with PBS and subsequently incubated 
for 1 minute in a pre-extraction buffer containing 
Triton-X-100 (0.5% Triton-X-100; 20 mM HEPES-KOH, 
pH 7.9; 50 mM NaCl; 3 mM MgCl2 and 300 mM sucrose) 
[42]. After rinsing with PBS, the cells were fixed by 
incubating them for 15 minutes in 4% paraformaldehyde 
in PBS, followed by another wash in PBS.
Immunofluorescence
EdU was detected with the use of a Click-IT® 
reaction. First the cells were permeabilized with 0.5% 
Triton-X-100 for 30 minutes, then they were washed twice 
with 3% BSA in PBS. Next, the cells were incubated for 
45 minutes at room temperature in a cocktail containing 
a final dilution of 43 mM Tris-HCl pH 7.5, 1.6 mM 
CuSO4·5H2O, 25 μM ATTO 390 Azide (ATTO-TEC 
GmbH) and 1 mM Ascorbic Acid. Before labelling RAD51, 
the cells were washed once more with 3% BSA and 
continued by a wash step (three times a short wash and two 
times 10 minutes incubation with PBS 0.1% Triton-X-100), 
followed by 30 minutes blocking in PBS+ (0.5% BSA and 
0.15% Glycine in PBS), overnight incubation at 4 °C with 
the first antibody in PBS+, another wash step, incubation 
with secondary antibody for two hours at room temperature. 
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After another wash step and a short wash in PBS only, 
the samples were embedded in Vectashield (Vector 
Laboratories) and sealed with nail polish.
Antibodies
For immunoblotting, the following antibodies and 
dilutions were used: mouse anti-BRCA2 (1:1000, OP95, 
Ab-1, Merck Millipore), mouse anti-PARP-1 (1:5000, 
C2-10, Enzo Lifesciences), mouse anti-HSP90 (1:1000, 
AC88, Abcam) and HRP-conjugated Sheep anti-mouse 
IgG (H+L) (1:2000, Jackson ImmunoResearch). For 
immunofluorescence rabbit anti-RAD51 (1:10000, [43]) and 
an Alexa Fluor® 594 goat anti-mouse (1:1000) were used.
Image acquisition and foci counting
The images were obtained with a Leica TCS SP5 
confocal microscope, using the 63x oil immersion (n.a. 
1.4) objective with an image size of 1024 x 1024 pixels 
and 82 x 82 μm. Per coverslip, at least four areas that 
contained EdU-positive cells were imaged in Z-stacks with 
14 slices and an increment of 1 μm. Before image analysis, 
maximum projections were made using FIJI image 
analysis software (Image J1.50i, [41]). For quantification 
of foci a homemade image analysis macro within FIJI 
was used. In short, regions of interest (ROIs) in the EdU-
channel were selected, and within these ROIs a threshold 
was set for RAD51 positive spots using the MaxEntropy 
algorithm. The ‘Analyze Particles’ function was used to 
count particles with a minimum size of 0.05 nm and a 
maximum size of 5 nm.
Statistics
All graphs and statistical analyses were generated in 
GraphPad Prism 6.0. Statistical tests for each experiment 
can be found in the figure legends.
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